Faculty of Health Sciences
School of Medicine
Department of Haematology
A phase II/III, randomized, cross-over, open-label trail to demonstrate superiority of prophylaxis over on-demand therapy in previously treated subjects with severe Haemophilia A treated with plasma protein-free recombinant FVIII formulated with sucrose. - Researchers Involved
Pool, R
Potgieter, JJC
Prinsloo, A
|
